In consultation: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Consultation end date

Consultation end date

Type

Type

Guidance programme

Showing 1 to 21 of 21

TitleConsultationTypeConsultation end date
Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)Draft guidance consultationNICE guideline
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer ID6607Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Apadamtase alfa for treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency ID6192Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Guidance on the use of electroconvulsive therapyReview proposal consultationTechnology appraisal guidance
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]Draft guidanceTechnology appraisal guidance
Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy ID6659Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Decitabine–cedazuridine with venetoclax for treating acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Perioperative care in adultsQuality standard consultationQuality standard
MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremorDraft scope consultationInterventional procedures guidance
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]Draft guidanceTechnology appraisal guidance
Upadacitinib for treating giant cell arteritis [ID6299]Draft guidanceTechnology appraisal guidance
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]Draft guidanceTechnology appraisal guidance
Artificial Intelligence assisted echocardiography to support diagnosis of heart failure: Early Value AssessmentDraft guidanceHealth technology evaluation
Anaphylaxis: assessment and referral after emergency treatmentSurveillance consultationNICE guideline
Suspected Cancer: recognition and referral (update)Draft guidance consultationNICE guideline
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]Draft guidanceTechnology appraisal guidance
Statement of intent on NICE's approach to ongoing evaluations ahead of proposed changes to NICE's standard cost-effectiveness thresholdsNICE general consultationNICE general
Domestic AbuseDraft scope consultationNICE guideline

Results per page

  1. 10
  2. 25
  3. 50
  4. All